Haematological Drugs Affecting Lipid Metabolism and Vascular Health
Open Access
- 10 August 2022
- journal article
- review article
- Published by MDPI AG in Biomedicines
- Vol. 10 (8) , 1935
Abstract
Many drugs affect lipid metabolism and have side effects which promote atherosclerosis. The prevalence of cancer-therapy-related cardiovascular (CV) disease is increasing due to development of new drugs and improved survival of patients: cardio-oncology is a new field of interest and research. Moreover, drugs used in transplanted patients frequently have metabolic implications. Increasingly, internists, lipidologists, and angiologists are being consulted by haematologists for side effects on metabolism (especially lipid metabolism) and arterial circulation caused by drugs used in haematology. The purpose of this article is to review the main drugs used in haematology with side effects on lipid metabolism and atherosclerosis, detailing their mechanisms of action and suggesting the most effective therapies.Keywords
This publication has 107 references indexed in Scilit:
- Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinibLeukemia, 2013
- Factors correlated with improvement of endothelial dysfunction during rituximab therapy in patients with rheumatoid arthritisBiologics: Targets and Therapy, 2013
- Severe Peripheral Arterial Disease During Nilotinib TherapyJNCI: Journal of the National Cancer Institute, 2011
- High prevalence of obesity in acute promyelocytic leukemia (APL): implications for differentiating agents in APL and metabolic syndromeTherapeutic Advances in Hematology, 2011
- Dyslipidemia Induced by Drugs Used for the Prevention and Treatment of Vascular DiseasesThe Open Cardiovascular Medicine Journal, 2011
- Chronic Rapamycin Treatment Causes Glucose Intolerance and Hyperlipidemia by Upregulating Hepatic Gluconeogenesis and Impairing Lipid Deposition in Adipose TissueDiabetes, 2010
- All- trans -Retinoic Acid Represses Obesity and Insulin Resistance by Activating both Peroxisome Proliferation-Activated Receptor β/δ and Retinoic Acid ReceptorMolecular and Cellular Biology, 2009
- Improved Survival in Lymphoma Patients Receiving Sirolimus for Graft-Versus-Host Disease Prophylaxis After Allogeneic Hematopoietic Stem-Cell Transplantation With Reduced-Intensity ConditioningJournal of Clinical Oncology, 2008
- Regulation of lipid and lipoprotein metabolism by retinoidsJournal of the American Academy of Dermatology, 2001
- Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for LeukemiaNew England Journal of Medicine, 1986